Absci (ABSI) said Wednesday it has entered into a strategic collaboration with Advanced Micro Devices (AMD) to deploy AMD Instinct accelerators and ROCm software to power AI drug discovery workloads, including Absci's advanced de novo antibody design models.
As part of the collaboration, Advanced Micro Devices is also investing $20 million in Absci, structured as a private investment in public equity.
The collaboration will be featured at the 43rd Annual J.P. Morgan Healthcare Conference on Jan. 15, Absci said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.